Compliance with multidisciplinary team meeting management recommendations.
breast cancer
compliance
multidisciplinary meeting
outcomes
Journal
Asia-Pacific journal of clinical oncology
ISSN: 1743-7563
Titre abrégé: Asia Pac J Clin Oncol
Pays: Australia
ID NLM: 101241430
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
09
06
2019
accepted:
07
08
2019
pubmed:
12
9
2019
medline:
16
1
2020
entrez:
12
9
2019
Statut:
ppublish
Résumé
The objective of this study was to evaluate patient compliance with management recommendations given by a breast cancer multidisciplinary team (MDT), assess for reasons for noncompliance, and perform an exploratory assessment on breast cancer outcomes in noncompliant patients. A retrospective analysis of prospectively collected data was undertaken for patients selected by their primary clinician to be discussed at the MDT of Breast Cancer Research Centre-WA in Perth between 1st March 2011 and the 28th February 2016. The primary objective was the rate of compliance with MDT management recommendations. Secondary objectives included factors associated with noncompliance, rate of clinical trial uptake, and impact of treatment noncompliance on breast cancer events in a subgroup of early breast cancer (EBC) patients. A total of 2614 MDT management recommendations were made for 925 patients. Overall, 92% were compliant with all recommendations given. Clinical trial recruitment was successful in 84.1%. The reasons given for treatment noncompliance were fear of toxicity, choosing an alternative treatment, and treatment inconvenience. In a subset of 337 EBC patients, there was a significantly higher rate of contralateral breast cancer, distant recurrence, and breast cancer-specific death, P = .0016, in those who were noncompliant. Our study demonstrates a high rate of MDT treatment recommendation compliance and clinical trial recruitment. In a subgroup of EBC patients, noncompliance was associated with significantly worse outcomes. Attention to educating patients to minimize their fear of treatment toxicity and ensuring their understanding of evidence-based treatment may lead to lower rates of noncompliance.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
337-342Informations de copyright
© 2019 John Wiley & Sons Australia, Ltd.
Références
Breast Cancer Statistics [Internet]. Australia: Australian Government; 2018 [updated January 30, 2018]. Available from: https://breast-cancer.canceraustralia.gov.au/statistics.
Fleissig A, Jenkins V, Catt S, Fallowfield L. Multidisciplinary teams in cancer care: are they effective in the UK? Lancet Oncol. 2006;7(11):935-943.
Patkar V, Acosta D, Davidson T, Jones A, Fox J, Keshtgar M. Cancer multidisciplinary team meetings: evidence, challenges, and the role of clinical decision support technology. Int J Breast Cancer. 2011;2011:831605.
Rogers MJ, Matheson L, Garrard B, et al. Comparison of outcomes for cancer patients discussed and not discussed at a multidisciplinary meeting. Public Health. 2017;149:74-80.
Rusby JE, Gough J, Harris PA, MacNeill FA. Oncoplastic multidisciplinary meetings: a necessity or luxury? Ann R Coll Surg Engl. 2011;93(4):273-274.
Kesson EM, Allardice GM, George WD, Burns HJ, Morrison DS. Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women. BMJ. 2012;344:e2718.
van Hoeve J, de Munck L, Otter R, de Vries J, Siesling S. Quality improvement by implementing an integrated oncological care pathway for breast cancer patients. Breast. 2014;23(4):364-370.
Chirgwin J, Craike M, Gray C, Watty K, Mileshkin L, Livingston PM. Does multidisciplinary care enhance the management of advanced breast cancer?: evaluation of advanced breast cancer multidisciplinary team meetings. J Oncol Pract. 2010;6(6):294-300.
Krishnamurthy S, Bevers T, Kuerer HM, Smith B, Yang WT. Paradigm shifts in breast care delivery: impact of imaging in a multidisciplinary environment. AJR Am J Roentgenol. 2017;208(2):248-255.
West JG, Qureshi A, Liao SY, et al. Multidisciplinary management of ductal carcinoma in situ: a 10-year experience. Am J Surg. 2007;194(4):532-534.
Wright FC, De Vito C, Langer B, Hunter A. Multidisciplinary cancer conferences: a systematic review and development of practice standards. Eur J Cancer. 1990;43(6):1002-1010.
Houssami N, Sainsbury R. Breast cancer: multidisciplinary care and clinical outcomes. Eur J Cancer. 1990;42(15):2480-2491.
Taplin SH, Weaver S, Salas E, et al. Reviewing cancer care team effectiveness. J Oncol Pract. 2015;11(3):239-246.
Taylor C, Munro AJ, Glynne-Jones R, et al. Multidisciplinary team working in cancer: what is the evidence? BMJ. 2010;340:c951.
NHaMR Council. Ethical Considerations in Quality Assurance and Evaluation Activities. 2014.
Pattanasri M, Elder K, Nickson C, et al. Uptake of adjuvant breast cancer treatments recommended by multi-disciplinary meetings. ANZ J Surg. 2018. https://doi.org/10.1111/ans.14368.
Le Saux O, Falandry C. Toxicity of cancer therapies in older patients. Curr Oncol Rep. 2018;20(8):64.
Rosenberg SM, Partridge AH. New insights into nonadherence with adjuvant endocrine therapy among young women with breast cancer. J Natl Cancer Inst. 2015;107(10). 10.1093/jnci/djv245.
Schwentner L, Van Ewijk R, Kuhn T, et al. Exploring patient- and physician-related factors preventing breast cancer patients from guideline-adherent adjuvant chemotherapy-results from the prospective multi-center study BRENDA II. Support Care Cancer. 2016;24(6):2759-2766.
Kuba S, Ishida M, Nakamura Y, Taguchi K, Ohno S. Persistence and discontinuation of adjuvant endocrine therapy in women with breast cancer. Breast Cancer. 2016;23(1):128-133.
Aiello Bowles EJ, Boudreau DM, Chubak J, et al. Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer. J Oncol Pract. 2012;8(6):e149-e157.
Brockway JP, Shapiro CL. Improving adherence to endocrine therapy in women with HR-positive breast cancer. Oncology. 2018;32(5):235-237, 249.
Fontein DB, Nortier JW, Liefers GJ, et al. High non-compliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial. Eur J Surg Oncol. 2012;38(2):110-117.
Mordenti P, Capuano DL, Zanlari L, et al. Reduction of fear and acute toxicity from chemotherapy with a telephone call after the first cycle. J Pain Symptom Manage. 2013;46(2):e6-e9.
Gandhi S, Day L, Paramsothy T, et al. Oral anticancer medication adherence, toxicity reporting, and counseling: a study comparing health care providers and patients. J Oncol Pract. 2015;11(6):498-504.
Pandey KC, Revannasiddaiah S, Pant NK. Evaluation of factors in relation with the non-compliance to curative intent radiotherapy among patients of head and neck carcinoma: a study from the Kumaon region of India. Indian J Palliat Care. 2015;21(1):21-26.
Pan IW, Smith BD, Shih YC. Factors contributing to underuse of radiation among younger women with breast cancer. J Natl Cancer Inst. 2014;106(1):djt340.
Zhao H, Hei N, Wu Y, et al. Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ. Cancer. 2017;123(6):940-947.
Fernandes-Taylor S, Adesoye T, Bloom JR. Managing psychosocial issues faced by young women with breast cancer at the time of diagnosis and during active treatment. Curr Opin Support Palliat Care. 2015;9(3):279-284.
Guidolin K, Lock M, Brackstone M. Patient-perceived barriers to radiation therapy for breast cancer. Can J Surg. 2018;61(2):141-143.
Walker HE, Rosenberg SM, Stanton AL, Petrie KJ, Partridge AH. Perceptions, attributions, and emotions toward endocrine therapy in young women with breast cancer. J Adolesc Young Adult Oncol. 2016;5(1):16-23.
Lin JH, Zhang SM, Manson JE. Predicting adherence to tamoxifen for breast cancer adjuvant therapy and prevention. Cancer Prev Res. 2011;4(9):1360-1365.
Barcenas CH, Zhang N, Zhao H, et al. Anthracycline regimen adherence in older patients with early breast cancer. Oncologist. 2012;17(3):303-311.
Cheung WY, Lai EC, Ruan JY, Chang JT, Setoguchi S. Comparative adherence to oral hormonal agents in older women with breast cancer. Breast Cancer Res Treat. 2015;152(2):419-427.
Guth U, Myrick ME, Kilic N, Eppenberger-Castori S, Schmid SM. Compliance and persistence of endocrine adjuvant breast cancer therapy. Breast Cancer Res Treat. 2012;131(2):491-499.
Iwai M, Fuchikami H, Mizuno Y, et al. [Factors affecting adherence of breast cancer patients to adjuvant hormonal therapy and validation of the evaluation method]. Gan To Kagaku Ryoho. 2014;41(7):843-847.